Role of the bone marrow microenvironment in multiple myeloma

Journal of Bone and Mineral Research

Volumn 17, Issue 11, 2002, Pages 1921-1925

  Roodman, G David ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Bone marrow microenvironment; Multiple myeloma; Osteoblast; Osteoclast; RANKL

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEVINOLIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEASOME INHIBITOR; SIMVASTATIN; THALIDOMIDE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL MODEL; BONE DENSITY; BONE DISEASE; BONE MARROW; BONE MINERAL; CELL ADHESION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; REVIEW; SCID MOUSE; STROMA CELL; TUMOR CELL;

EID: 0036829305     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.11.1921     Document Type: Review

References (18)

1. Van Riet I, Hellebaut L, Vande Broek I, Vanderkerken K, Van Camp B 2001 Molecular interactions between multiple myeloma cells and endothelial cells. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
2. Anderson KC 2001 Novel therapeutic targets based on interactions of the myeloma cell and its bone marrow microenvironment. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
3. L and inhibits CD95/Fas-mediated apoptosis: A novel mechanism of immune evasion. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
4. 7 integrin in myeloma cells [abstract]. Abstract released (not presented) at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, June 26-27.
5. Roodman GD 2001 Blocking macrophage inflammatory protein-1α in myeloma cells decreases bone destruction and tumor burden by decreasing their homing capacity and growth in vivo. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
6. Epstein J 2001 Modulation of myeloma bone disease. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
7. Yaccoby S 2001 Myeloma-microenvironment interaction dynamics. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
8. Croucher P, Vanderkerken K 2001 Osteoprotegerin inhibits the development of myeloma bone disease in the 5T2MM murine model of myeloma. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
9. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y 2001 Deregulation of TRANCE and OPG by myeloma. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
10. Altamirano CV, Manyak S, Tang G, Parker K, Ma M, Sjak-Shie N, Vescio RA, Berenson JR 2001 The role of RANKL, RANK, and OPG in the pathogenesis of multiple myeloma. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
11. Oyajobi B 2001 Novel mechanisms mediating osteolysis in myeloma. Presented at The Role of the Bone Microenvironment in Multiple Myeloma, Chicago, IL, USA, June 26-27.
12. McGowan NW, Walker EJ, Macpherson H, Ralston SH, Helfrich MH 2001 Cytokine-activated endothelium recruits osteoclast precursors. Endocrinology 142:1678-1681.
13. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y 2000 Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161-164.
14. Kostenuik PJ, Shalhoub V 2001 Osteoprotegerin: A physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613-635.
15. Gardnerova M, Blanque R, Gardner CR 2000 The use of TNF family ligands and receptors and agents which modify their interaction as therapeutic agents. Curr Drug Targets 1:327-364.
16. Green JR 2001 Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol 28(2 Suppl 6):4-10.
17. Wang PS, Solomon DH, Mogun H, Avorn J 2000 HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216.
18. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H 2000 HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210.